Free Design Audit Available - Click Here for Details

AngioDynamics wins CE Mark for AlphaVac F18

AngioDynamics announced this week that it received CE Mark approval for its AlphaVac F18 system, which treats pulmonary embolism and removes thrombi and emboli.

AlphaVac F18 is an emergent first-line device the company designed for the non-surgical removal of thromboemboli from the pulmonary arteries and for the treatment of pulmonary embolisms. It has an ergonomic handle, an 18Fr cannula with an 85-degree angle, an obturator and a waste bag assembly.

“The CE Mark represents a major step forward in enhancing patient care and safety for endovascular therapies in the EU, a market with a higher prevalence of PE when compared to the United States,” AngioDynamics’ Senior Vice President and General Manager of Endovascular Therapies Laura Piccinini said in a news release. “This designation allows us to broaden our reach and provide innovative solutions to more healthcare professionals treating patients diagnosed with PE – on an increasingly global scale.

Sign up for Blog Updates